Home › Research › Biomarkers
Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch
Christopher Andrew Brown, Nidhi S. Mundada, Katheryn A Q Cousins, Niyousha Sadeghpour, Xueying Lyu, Emily McGrew, Magdalena Korecka, Alice S. Chen‐Plotkin et al.. JAMA Neurology, 2025-12-15
Topic: Brain proteins, microglia and lab models
Plain-language summary
A total of 365 participants (mean [SD] age, 75.4 [7.9] years; 192 female [52.6%]) in the ADNI tau-PET group and 524 participants (mean [SD] age, 77.1 [7.9] years; 268 male [51.1%]) in the ADNI p-tau217 group were selected from the 998 individuals who were Aβ+ in the ADNI cohort and used to generate tau-clinical mismatch models with 55.6% to 57.1% classified as canonical (CDR-SB commensurate to tau), 23.7% to 24.7% as resilient (CDR-SB tau). Vulnerable groups had evidence of greater likelihood of copathology, with TDP-43 neurodegeneration patterns and α-synuclein positivity. Mismatch groups showed diverging clinical trajectories with earlier cognitive impairment in vulnerable groups and later impairment in resilient individuals. Similar findings were seen when applied to an independent dataset of 244 individuals (mean [SD] age, 73.7 [6.8] years; 139 female [57.0%]) of the 248 who were Aβ+ in Penn-ADRC cohort. Finally, these models were applied to a cohort receiving antiamyloid therapy to show the utility of this method for predicting individual cognitive trajectories during therapy. Conclusion and Relevance: Results of this cohort study suggest that tau-clinical mismatch identified individuals more likely to have an accelerated disease course due to the presence of copathology and those exhibiting greater cognitive resilience to disease pathology. These models provide an important tool that can be implemented in clinical practice to provide improved individualized prognosis and, potentially, monitoring of response to disease-modifying therapy.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 365 participants. Models of tau-clinical mismatch identified people with accelerated disease course due to copathology and those with greater cognitive resilience to pathology. Reported effect size: 52.6%; 51.1%; 55.6% to 57.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Brown, C. A., Mundada, N. S., Cousins, K. A. Q., Sadeghpour, N., Lyu, X., McGrew, E., et al. (2025). Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2025.4974
Vancouver
Brown CA, Mundada NS, Cousins KAQ, Sadeghpour N, Lyu X, McGrew E, et al. Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch. JAMA Neurology. 2025. doi:10.1001/jamaneurol.2025.4974. PMID: 41396614.
BibTeX
@article{brown2025-41396614,
author = {Brown, Christopher Andrew and Mundada, Nidhi S. and Cousins, Katheryn A Q and Sadeghpour, Niyousha and Lyu, Xueying and McGrew, Emily and Korecka, Magdalena and Chen‐Plotkin, Alice S. and others},
title = {{Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch}},
journal = {JAMA Neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.4974},
pmid = {41396614},
url = {https://doi.org/10.1001/jamaneurol.2025.4974}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A total of 365 participants (mean [SD] age, 75.4 [7.9] years; 192 female [52.6%]) in the ADNI tau-PET group and 524 participants (mean [SD] age, 77.1 [7.9] years; 268 male [51.1%]) in the ADNI p-tau217 group were selected from the 998 individuals who were Aβ+ in the ADNI cohort and used to generate tau-clinical mismatch models with 55.6% to 57.1% classified as canonical (CDR-SB commensurate to tau), 23.7% to 24.7% as resilient (CDR-SB < tau), and 19.3% to 19.7% as vulnerable (CDR-SB > tau).
- Vulnerable groups had evidence of greater likelihood of copathology, with TDP-43 neurodegeneration patterns and α-synuclein positivity.
- Mismatch groups showed diverging clinical trajectories with earlier cognitive impairment in vulnerable groups and later impairment in resilient individuals.
- Similar findings were seen when applied to an independent dataset of 244 individuals (mean [SD] age, 73.7 [6.8] years; 139 female [57.0%]) of the 248 who were Aβ+ in Penn-ADRC cohort.
- Finally, these models were applied to a cohort receiving antiamyloid therapy to show the utility of this method for predicting individual cognitive trajectories during therapy.
Why it matters
Models of tau-clinical mismatch identified people with accelerated disease course due to copathology and those with greater cognitive resilience to pathology. These models may help predict individual cognitive trajectories, including during antiamyloid therapy.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants365
- Effect size52.6%; 51.1%; 55.6% to 57.1%
- Evidence strengthModerate
How this study scored 61/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 365 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Brian J. Lopresti: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41396614) |
| Free to read | 2 / 2 | Free to read |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.4974
- PubMed: 41396614
- Original source →
- Free full text: JAMA Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.